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Abstract 
Neurological and psychiatric conditions frequently overlap in neuro-oncology. This overlap-
ping negatively affects patients’ quality of life and decreases the ability of providers to man-
age specific symptoms by therapy modulation, especially when psychopharmacotherapy 
needs to be prescribed. We describe here a patient with recurrent brain tumor, symptomatic 
epilepsy and depression who developed Pisa syndrome and parkinsonism after several 
months of valproic acid use. An accurate recognition of symptoms and treatment side effect 
allowed an appropriate clinical approach so as to rapidly improve both movement disorder 
and depression without increasing the risk of developing seizure. This has improved the au-
tonomy and quality of life in a patient with poor prognosis. © 2016 The Author(s) 
 Published by S. Karger AG, Basel 
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Case Report 
A 59-year-old inpatient was admitted to the neurological cancer center Istituto Neuro-
logico ‘Carlo Besta’ for worsened condition. He had been diagnosed 3 years before with re-
current high-grade glioma and underwent two surgeries, radiotherapy plus chemotherapy. 
He suffered from epilepsy in therapy with levetiracetam. Since this treatment was poorly 
tolerated for dysphoric status, it was changed to valproic acid (VPA) (900 mg/day). Howev-
er, 6 months before hospitalization – 3 after the new antiepileptic drug –, during periodical 
outpatient clinical evaluation, a depressed mood emerged, with work retirement, somatiza-
tion, loss of weight, and sleep disorder. Furthermore, cognitive impairment seemed to be 
present, with short-term memory deficit and dyscalculia. The psychopathological history of 
the patient was characterized by the presence of hyperthymic temperament and subsyn-
dromal hypomania. A previous depressive episode had been reported during young adult-
hood. 
Six months before hospitalization, he started taking paroxetine (20 mg/day), with slight 
improvement of mood at clinical global impression. The patient needed to be hospitalized, 
due to gait and upright posture disturbances. Brain magnetic resonance imaging (fig. 1) 
showed removal of bulky lesion located in the right parietal peritrigonal region. There was 
marked dilatation of the temporal horn, the third ventricle and the left lateral ventricle. 
Widespread signal alteration was prevalent in the white matter and in the splenium. After 
administration of gadolinium, it was not possible to observe clear signs of dissemination in 
the supratentorial and infratentorial region. 
The electroencephalogram described rather unstable background activity, better on the 
left hemisphere, slower and more unstable on the right. Multifocal epileptiform abnormali-
ties were observed in the right hemisphere. On the clinical examination, the patient showed 
abnormal posture with sustained lateral bending of the trunk along the sagittal plane on the 
right side. At the same time, bradykinesia and rigidity of the four limbs were present. Pos-
tural instability and falling were present as well. Tendon reflexes were brisk without pyram-
idal signs. The patient also showed tremor of the voice and hypophonia, hypomimia, short 
shuffling steps, trouble starting to walk, and difficulty in turning. The signs were symmet-
rical. 
The blood level of VPA was 63 µg/ml (normal value = 40–100), and ammonemia was 57 
µg/dl (normal value = 27–102). During the hospitalization, a pharmacological change was 
decided that involved tapering off VPA and getting on therapy with lamotrigine (LMT) up to 
a dose of 200 mg/day, with blood level 7.2 mg/l (normal value = 3–14). The patient was 
discharged with a partial regression of symptoms. In the following weeks, neurological and 
psychiatric condition improved. (table 1) 
Discussion 
Depression accounts for 15–20% of patients with glioma within 8 months after diagno-
sis [1], even if various longitudinal studies have shown significant improvements in the fol-
lowing months. The precise cause of the depression remains unclear. Previous medical his-
tory of depression may predict an increased risk of depression in glioma. Untreated depres-
sion is an established risk factor for mortality in cancer and neurological disease [2]. 
Selective serotonin reuptake inhibitors (SSRIs) are associated with improvements in 
disability and neurological impairment after cerebrovascular disease. Conflicting data are 
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available with regard to glioma patients. Extrapyramidal symptoms (EPS) have been report-
ed with different classes of antidepressants; they seem not to be dose-related and to be due 
to short-term or long-term use. The literature concerning SSRIs is controversial, because not 
the class in itself is responsible for EPS but the patient’s own sensitivity. In any case, an in-
crease of 5HT, due to the SSRIs reuptake inhibition, can reduce the dopaminergic tone at 
basal ganglia level (inducing EPS), as well as at the anterior cingulate and frontal cortex, 
potentially inducing emotional blunting [3]. However, SSRIs are currently used in Parkinson 
disease and may improve depression [4]. 
Epilepsy occurs in about 40–60% of patients with high-grade glioma, and is itself an un-
favorable prognostic factor [5]. Alper et al. [6] performed a large meta-analysis on seizure 
risk and found an increased risk linked to the use of the antidepressants bupropion and 
clomipramine. Most antidepressants included in this study showed no association with an 
increased seizure risk in therapeutic doses, and some were associated with a reduced risk 
[2]. Furthermore, a systematic revision of the Cochrane database did not appear to show any 
significant worsening of seizures [7]. 
VPA is a well-known antiepileptic drug indicated for the prevention of affective episodes 
[8]. VPA was identified as one of the drugs capable of inducing parkinsonism in elderly pa-
tients in the French Pharmacovigilance Database. A similar association was found in a recent 
literature review [9]. Most cases were shown to be reversible upon VPA discontinuation, 
although no predictors of reversibility were identified. VPA acts as mild inhibitor of cyto-
chrome enzyme system (CYP450) and can induce pharmacokinetic interactions with drugs 
metabolized by CYP2D6 and CYP2C9 (e.g. SSRIs) with increase of plasma levels [10]. 
EPS refers to a condition of sustained lateral bending of the trunk, associated or not with 
rotation of the spine along the sagittal plane. It was originally described by Ekbom et al. [11] 
in 1972 in patients on psychiatric drugs. 
LMT is often used with severe epilepsy (focal and general onset seizures) [12], and is 
recommended in bipolar maintenance when depression is prominent. It also plays a role in 
treating acute bipolar and unipolar depression, for intrinsic antidepressant activity [13]. 
Some papers have described the use of LMT in hard to treat depression [14, 15] due to the 
weak CYP450-mediated metabolic interaction with SSRIs. 
Consistently with the literature, tapering and changing of antiepileptic drugs with LMT 
has improved neurological and psychiatric symptoms. The choice to remove VPA was due to 
a less significant EPS (percentage and severity) compared to what is reported in association 
with antidepressants. The scores of the psychometric scales showed a decrease of depres-
sion and disability, with recovery of daily living activity. 
Conclusion 
Neurological and psychiatric conditions frequently overlap in neuro-oncology. This 
overlapping negatively affects patients’ quality of life and decreases the ability of providers 
to manage specific symptoms by therapy modulation, especially when psychopharma-
cotherapy needs to be prescribed. 
In the present case, an oncology patient suffered from depression and epilepsy. Howev-
er, an accurate recognition of symptoms and treatment side effects allowed an appropriate 
clinical approach so as to rapidly improve both movement disorder and depression without 
increasing the risk of developing seizure. This improved the autonomy and quality of life in a 
patient with poor prognosis. 
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Statement of Ethics 
The patient had the opportunity to discuss with his physician in charge the opportunity 
to publish his clinical case without revealing any personal data in order to share and im-
prove clinical knowledge and practice. The patient signed an inform consent and gave us the 
authorization to publish his case. Authors guaranteed the anonymity of the patient. 
Disclosure Statement 
The authors declare that the study presented received no financial support. The authors 
declare no conflict of interest. 
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Fig. 1. Magnetic resonance image of the brain. 
 
 
 
 
Table 1. Clinical characteristics over time 
    
    
 T0 T1 T2 
    
    
UPDRS III 52/108 007/108 000/108 
MMSE 25/30 027/30 029/30 
Clock Drawing Test 01 001 001 
HAM-D 25 004 003 
MADRS 32 010 006 
ADL 05/6 006/6 006/6 
IADL 01/8 006/8 008/8 
Barthel Index 70/100 100/100 100/100 
    
    
T0 = On admission to hospital; T1 = 1 month later; T2 = 3 months 
later; UPDRS = Unified Parkinson Disease Rating Scale (part III motor 
examination); MMSE = Mini Mental State Evaluation; HAM-D = Hamil-
ton Rating Scale for Depression; MADRS = Montgomery Asberg De-
pression Rating Scale; ADL = Activities of Daily Living; IADL = Instru-
mental Activities of Daily Living. 
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